Improving Outcomes in HER2-Positive Breast Cancer: Analysis and Application of Evolving Data and Best Practices

por Abraham, Jame, Mayden, Kelley D.
Publicado 2020

Pseudocirrhosis in Breast Cancer – Experience From an Academic Cancer Center

por Gopalakrishnan, Dharmesh, Shajihan, Ain, Purysko, Andrei S., Abraham, Jame
Publicado 2021

Breast Cancer Pathology, Receptor Status, and Patterns of Metastasis in a Rural Appalachian Population

por Vona-Davis, Linda, Rose, David P., Gadiyaram, Vijaya, Ducatman, Barbara, Hobbs, Gerald, Hazard, Hannah, Kurian, Sobha, Abraham, Jame
Publicado 2014

Radiomic predicts early response to CDK4/6 inhibitors in hormone receptor positive metastatic breast cancer

por Khorrami, Mohammadhadi, Viswanathan, Vidya Sakar, Reddy, Priyanka, Braman, Nathaniel, Kunte, Siddharth, Gupta, Amit, Abraham, Jame, Montero, Alberto J., Madabhushi, Anant
Publicado 2023

Genetic Counseling and Germline Testing in the Era of Tumor Sequencing: A Cohort Study

por Klek, Stefan, Heald, Brandie, Milinovich, Alex, Ni, Ying, Abraham, Jame, Mahdi, Haider, Estfan, Bassam, Khorana, Alok A, Bolwell, Brian J, Grivas, Petros, Sohal, Davendra P S, Funchain, Pauline
Publicado 2020

Endocrine therapy and related issues in hormone receptor-positive early breast cancer: a roundtable discussion by the breast cancer therapy expert group (BCTEG)

por Abraham, Jame, Caldera, Humberto, Coleman, Robert, Elias, Anthony, Goetz, Matthew P., Kittaneh, Muaiad, Lower, Elyse, Mahtani, Reshma, Terry Mamounas, E., Pegram, Mark, Rugo, Hope, Schwartzberg, Lee, Traina, Tiffany, Vogel, Chuck
Publicado 2018

Time to initial cancer treatment in the United States and association with survival over time: An observational study

por Khorana, Alok A., Tullio, Katherine, Elson, Paul, Pennell, Nathan A., Grobmyer, Stephen R., Kalady, Matthew F., Raymond, Daniel, Abraham, Jame, Klein, Eric A., Walsh, R. Matthew, Monteleone, Emily E., Wei, Wei, Hobbs, Brian, Bolwell, Brian J.
Publicado 2019

Correction: Time to initial cancer treatment in the United States and association with survival over time: An observational study

por Khorana, Alok A., Tullio, Katherine, Elson, Paul, Pennell, Nathan A., Grobmyer, Stephen R., Kalady, Matthew F., Raymond, Daniel, Abraham, Jame, Klein, Eric A., Walsh, R. Matthew, Monteleone, Emily E., Wei, Wei, Hobbs, Brian, Bolwell, Brian J.
Publicado 2019

Association of Peritumoral Radiomics With Tumor Biology and Pathologic Response to Preoperative Targeted Therapy for HER2 (ERBB2)–Positive Breast Cancer

por Braman, Nathaniel, Prasanna, Prateek, Whitney, Jon, Singh, Salendra, Beig, Niha, Etesami, Maryam, Bates, David D. B., Gallagher, Katherine, Bloch, B. Nicolas, Vulchi, Manasa, Turk, Paulette, Bera, Kaustav, Abraham, Jame, Sikov, William M., Somlo, George, Harris, Lyndsay N., Gilmore, Hannah, Plecha, Donna, Varadan, Vinay, Madabhushi, Anant
Publicado 2019

Machine Learning–Based Risk Assessment for Cancer Therapy–Related Cardiac Dysfunction in 4300 Longitudinal Oncology Patients

por Zhou, Yadi, Hou, Yuan, Hussain, Muzna, Brown, Sherry‐Ann, Budd, Thomas, Tang, W. H. Wilson, Abraham, Jame, Xu, Bo, Shah, Chirag, Moudgil, Rohit, Popovic, Zoran, Cho, Leslie, Kanj, Mohamed, Watson, Chris, Griffin, Brian, Chung, Mina K., Kapadia, Samir, Svensson, Lars, Collier, Patrick, Cheng, Feixiong
Publicado 2020

Safety and Efficacy of T-DM1 Plus Neratinib in Patients With Metastatic HER2-Positive Breast Cancer: NSABP Foundation Trial FB-10

por Abraham, Jame, Montero, Albert J., Jankowitz, Rachel C., Salkeni, Mohamad Adham, Beumer, Jan H., Kiesel, Brian F., Piette, Fanny, Adamson, Laura M., Nagy, Rebecca J., Lanman, Richard B., Sperinde, Jeff, Huang, Weidong, Allegra, Carmen J., Srinivasan, Ashok, Wang, Ying, Pogue-Geile, Katherine L., Lucas, Peter C., Jacobs, Samuel A.
Publicado 2019

Adrenal-permissive HSD3B1 genetic inheritance and risk of estrogen-driven postmenopausal breast cancer

por Kruse, Megan L., Patel, Mona, McManus, Jeffrey, Chung, Yoon-Mi, Li, Xiuxiu, Wei, Wei, Bazeley, Peter S., Nakamura, Fumihiko, Hardaway, Aimalie, Downs, Erinn, Chandarlapaty, Sarat, Thomas, Mathew, Moore, Halle C.F., Budd, George T., Tang, W.H. Wilson, Hazen, Stanley L., Bernstein, Aaron, Nik-Zainal, Serena, Abraham, Jame, Sharifi, Nima
Publicado 2021

NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2(+) breast cancer

por Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Publicado 2019

Correction to: NSABP FB-7: a phase II randomized neoadjuvant trial with paclitaxel + trastuzumab and/or neratinib followed by chemotherapy and postoperative trastuzumab in HER2+ br...

por Jacobs, Samuel A., Robidoux, André, Abraham, Jame, Pérez-Garcia, José Manuel, La Verde, Nicla, Orcutt, James M., Cazzaniga, Marina E., Piette, Fanny, Antolín, Silvia, Aguirre, Elena, Cortes, Javier, Llombart-Cussac, Antonio, Di Cosimo, Serena, Kim, Rim S., Feng, Huichen, Lipchik, Corey, Lucas, Peter C., Srinivasan, Ashok, Wang, Ying, Song, Nan, Gavin, Patrick G., Balousek, April D., Paik, Soonmyung, Allegra, Carmen J., Wolmark, Norman, Pogue-Geile, Katherine L.
Publicado 2020